Showing 2631-2640 of 5621 results for "".
- CooperVision Extends Deadline for Science and Technology Awards Proposalshttps://modernod.com/news/coopervision-extends-deadline-for-science-and-technology-awards-proposals/2477688/CooperVision has extended the submission deadline for its
- Higher Rates of COVID-19 Infection and Death for People With Parkinson Diseasehttps://modernod.com/news/higher-rates-of-covid-19-infection-and-death-for-people-with-parkinson-disease/2477683/A paper accepted for publication in Movement Disorders suggests that people with Parkinson disease (PD) with longer disease duration (mean 12.7 years) may be more susceptible to infection with the SARS-CoV2 virus (COVID-19), according to an
- Mojo Vision Raises Additional $51 Million to Develop Smart Contact Lenshttps://modernod.com/news/mojo-vision-raises-additional-51-million-to-develop-smart-contact-lens/2477678/Mojo Vision announced it has raised more than $51 million in a Series B-1 investment round to propel the development of its smart contact lens, Mojo Lens. This new round brings Mojo Vision’s total funding to date to more than $159 million. In January, Mojo announced that it is in th
- AAO, ASCRS, and OOSS Develop Checklist for Reopening Ophthalmic Surgery Centershttps://modernod.com/news/ooss-aao-and-ascrs-develop-checklist-for-reopening-ophthalmic-surgery-centers/2477669/To support the safe reopening of care, the American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), and the Outpatient Ophthalmic Surgery Society (OOSS), developed a checklist<
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Congress Reaches Deal That Includes $75B for Hospitals After Requests From Providershttps://modernod.com/news/congress-reaches-deal-that-includes-75b-for-hospitals-after-requests-from-providers/2477629/Congressional and White House leaders have reached a deal to provide $75 billion for hospitals and another $25 billion for testing, according to a report from CNN, as
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech